Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Combination Chemotherapy + G-CSF in Elderly NHL
NCT00003113Phase 2
Key facts
- Status
- Terminated
- Start
- Jul 1997
- Primary completion
- Dec 2002
- Countries
- 1
- Sponsor
- Case Comprehensive Cancer Center
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Conditions
- non-Hodgkin lymphoma (NHL)
01
Overview
Phase 2, open-label, single-arm trial of filgrastim, cyclophosphamide, etoposide, lomustine and procarbazine in non-Hodgkin lymphoma (NHL), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Feasibility of oral combination chemotherapy, Toxicity and 3 more. Started Jul 1997; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Oral Combination Chemotherapy + G-CSF
Etoposide, Cyclophosphamide, Procarbazine, Lomustine, Filgrastim
03
Who it enrols
Elderly patients (>=60) with biopsy-proven stage I-IV intermediate to high grade non-Hodgkin's lymphoma, no prior chemotherapy, and adequate organ function. Excludes CNS lymphoma.
04
Endpoints
Primary
Feasibility of oral combination chemotherapy
Toxicity
Objective Response Rate
Response Duration
Survival
Beyond the preview
Go deeper on NCT00003113.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003113.